ClinicalTrials.gg
CompletedNCT02162784Updated Jun 3, 2015

Efficacy Study of SYN006 HFA MDI in Asthma Patients

A Phase 2 interventional study of Budesonide/Procaterol, 180/10mcg X1 and Budesonide/procaterol 180/10 mcg X 2 in Asthma, sponsored by Intech Biopharm Ltd.. Completed at 3 sites in Taiwan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-06-03.

Sponsored by Intech Biopharm Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.

Enrollment
64th of 72
39 · median 274
Started
2013
with 2 others
Phase 2
16 of 88
4 open now
Registered
26th of 88
by date
Lead sponsor
7 of 88
Intech Biopharm Ltd.

Among the 88 studies in Asthma with a site in Taiwan, this one is the 64th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2013, is one of 16 in phase 2, and was the 26th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Asthma with a site in Taiwan, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the dose response of SYN006 HFA MDI, which is a combination drug product of budesonide and procaterol hydrochloride, in asthma patients. Patients with mild to moderate asthma will be recruited. There will be two study medication administered in this study. The investigational medication is SYN006 (Budesonide/Procaterol hydrochloride, 180 mcg/10 mcg per inhalation) and the active comparative medication is Ventolin (Salbutamol sulfate 100 mcg per inhalation). The study medication will be administered by oral inhalation with the supervision of the investigator or a qualified staff.

Read the detailed description

Three treatments will be administered in a patient:

  • A. Two inhalations of Ventolin 100 mcg,
  • B. One inhalation of SYN006 180/10 mcg,
  • C. Two inhalations of SYN006 180/10 mcg.

Patients will be received the study treatment according to one of the six treatment sequences according to the randomization schedule:

  1. A-B-C,
  2. B-A-C,
  3. C-A-B,
  4. C-B-A,
  5. A-C-B,
  6. B-C-A.

The efficacy endpoint is

  • The change in Forced Expiratory Volume in 1 second (FEV1) within 6 hours.
  • The change in Peak Expiratory Flow Rate (PEFR) within 6 hours.
  • The change in Force Vital Capacity (FVC) within 6 hours.
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient aged >= 16 years old
  • History of >=12% and 200 ml increase after inhalation of short-acting beta 2-agonist;
  • Pre-bronchodilator FEV1 > 60% and \< 90% of predicted normal value at enrollment;
  • Ability to inhale correctly through MDI inhaler
  • Written obtained.
  • Diagnosis of mild to moderate persistent asthma according to GINA with a documented history of at least 6 months duration.

Mild Persistent:

  1. Symptoms more than once a week but less than once a day
  2. Nocturnal symptoms more than twice a month
  3. Exacerbations may affect activity and sleep
  4. FEV1 or PEF >= 80% predicted
  5. PEF or FEV1 variability \< 20 - 30%

Moderate Persistent:

  1. Symptoms daily
  2. Nocturnal symptoms more than once a week
  3. Exacerbations may affect activity and sleep
  4. Daily use of inhaled short-acting beta2-agonist
  5. FEV1 or PEF > 60% - \< 80% predicted
  6. PEF or FEV1 variability > 30%

Exclusion criteria

Exclusion Criteria:

  • Currently uncontrolled asthma according to GINA guideline;
  • Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;
  • Inability to carry out pulmonary function testing;
  • Severe asthma associated with reduced lung function;
  • or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer), neurological or haematological diseases;
  • Abnormal at enrollment;
  • History of near-fatal asthma and/or admission intensive care unit because of asthma;
  • History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias;
  • Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous 6 months at enrollment;
  • Hospitalization for asthma during the past 3 months at enrollment;
  • Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 3 months at enrollment;
  • Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years;
  • History of alcohol or drug abuse;
  • Pregnant or lactating females or not able to exclude pregnancy during the study period;
  • Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;
  • Patients who received any new drug within the last 3 months at enrollment;
  • Patients who have been previously enrolled in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Budesonide/procaterol 180/10mcg X1

    HFA MDI, oral inhalation, 180/10mcg, one puff

    Drug: Budesonide/Procaterol, 180/10mcg X1

  • Experimental
    Budesonide/Procaterol, 180/10mcg X2

    HFA MDI, oral inhalation, two puffs

    Drug: Budesonide/procaterol 180/10 mcg X 2

  • Active comparator
    Albuterol HFA MDI 100 mcg X2

    HFA MDI, oral inhalation, 100mcg, two puffs

    Drug: Albuterol HFA MDI 100mcg X2

Interventions

  • DrugBudesonide/Procaterol, 180/10mcg X1

    one puff

    Also known as: Synbitide

  • DrugBudesonide/procaterol 180/10 mcg X 2

    2 puffs

    Also known as: Synbitide

  • HFA MDI, 100mcg, 2 puffs

    Also known as: Ventolin

06

What researchers measure

Primary outcomes

  1. The variation of study medications by the area under curve of FEV1 from 0 to 120 minutes (AUC0-120min ) after inhalation.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

Secondary outcomes

  1. The change in Forced Expiratory Volume in 1 second (FEV1) of study medication.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

  2. The change in Peak Expiratory Flow Rate (PEFR) of study medication.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

  3. The change in Forced Vital Capacity (FVC) of study medication.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

  4. The variation of study medications by the area under curve of PEFR from 0 to 120 minutes (AUC0-120min ) after inhalation.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

  5. The variation of study medications by the area under curve of FVC from 0 to 120 minutes (AUC0-120min ) after inhalation.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

Other outcomes

  1. Adverse events, vital signs, abnormal ECG outcome.

    Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation

07

Study locations

3 sites
  • Chung Shan Medical University Hospital
    TaiChung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Tri-Service General Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jun 13, 2014
Start
Feb 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Jun 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02162784
Lead sponsor
Intech Biopharm Ltd.
Responsible party
Sponsor
First posted
Jun 13, 2014
Start date
Feb 2013
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Jun 3, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion